Community Contributor
Member since 2025
Views93Total number of views
Followers4Total number of followers
Comments0Total number of comments

No bio added yet

No link added
NarrativesWatchlists
ALZN logo
Alzamend Neuro

Alzamend Neuro's Novel Lithium Formulation Will Target Major Mental Health Challenges

Catalysts AL001 : a novel lithium formulation targeting Alzheimer's disease, Bipolar Disorder, Major Depressive Disorder (MDD), and PTSD. Phase II studies show promising safety/efficacy, with trials ongoing as of 2025.Read more

View narrative
93
users have viewed this narrative
1users have liked this narrative
0users have commented on this narrative
5users have followed this narrative
US$12
84.5% undervalued intrinsic discount
Fair Value
Profit Margin
20.86%
Future PE
29.37x
Price in 2030
US$0